Nexavar improves survival in liver cancer
Published: 2010-10-06 06:53:00
Updated: 2010-10-06 06:53:00
According to a press release from Bayer Healthcare, which was held to mark the 5-year launching of Nexavar (sorafenib) in Korea, the medication appears to improve overall survival among patients with hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC) who have not received prior therapy...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.